



UMEÅ UNIVERSITET

Hybrid Imaging: The Story so Far and What to Expect Next



Katrine Riklund

Professor/Consultant, Radiology and Nuclear medicine

Umeå university Hospital Sweden



The Weather



Hybrid Imaging

A combination of imaging with different type of information that is synergistic!


→

the whole information is larger than the sum of the image data set



→

= > 2



The Nobel Prize in Physics 1901



**Wilhelm Conrad
Röntgen**
1845-1923



"in recognition of the extraordinary services he has rendered by the discovery of the remarkable rays subsequently named after him"

The Nobel Prize in Physics 1903



Henri Becquerel
1852-1908

"in recognition of the extraordinary services he has rendered by his discovery of spontaneous radioactivity"



Pierre Curie
1859-1906

"in recognition of the extraordinary services they have rendered by their joint researches on the radiation phenomena discovered by Professor Henri Becquerel"



**Marie Curie
Skłodowska**
1867-1934

The Nobel Prize in Chemistry 1911



Marie Curie, born Sklodowska

1867-1934

"in recognition of her services to the advancement of chemistry by the discovery of the elements radium and polonium, by the isolation of radium and the study of the nature and compounds of this remarkable element"



The Nobel Prize in Chemistry 1935



Irène Joliot-Curie

1897-1956



Frédéric Joliot

1900-1958

"in recognition of their synthesis of new radioactive elements"

The Nobel Prize in Chemistry 1943

George de Hevesy

Hungary

Stockholm university

1885 - 1966





"for his work on the use of isotopes as tracers in the study of chemical processes"

History



Early Theranostic agent - ^{131}I -iodide



The Nobel Prize in Physiology or Medicine 1979



Allan M. Cormack
1924-1998





Godfrey N. Hounsfield
1919-2004


"for the development of computer assisted tomography"

“Anatometabolic” Tumor Imaging: Fusion of FDG PET with CT or MRI to Localize Foci of Increased Activity

Richard L. Wahl, Leslie E. Quint, Richard D. Cieslak, Alex M. Aisen, Robert A. Koeppe and Charles R. Meyer



Fused Image Tomography: Where Do We Go From Here?



In my recent "Annual Meeting Highlights" (see *Newsline*, August, p. 13N), I suggested that the exact portrayal of anatomy (through CT) and regional biochemistry (PET), obtained with the same imaging gantry without moving the patient, represents an important integrating force in nuclear medicine.

SPECT/CT as well as PET/CT should be developed, but that fusion of the images from PET instruments should be developed cannot be developed by industry simulation. Several qualifying statements need to be made. First, the persons responding to the survey were those who are sufficiently interested

—Henry N. Wagner, Jr., MD

THE JOURNAL OF NUCLEAR MEDICINE • Vol. 40 • No. 9 • October 1999

(1) The ability to obtain fused PET data and CT images without moving the patient is an important advance. 97%

(2) The quality of the CT images should be clinically interpretable themselves. 100%

"I think fusion is overblown in reputation. Good nuclear physicians can correlate just as well using internal landmarks." 80%

"The PET business will go to the radiologist who will in fact own / control the CT." as a team.

A Combined PET/CT Scanner for Clinical Oncology

Thomas Beyer, David W. Townsend, Tony Brun, Paul E. Kinahan, Martin Charron, Raymond Roddy, Jeff Jerin, John Young, Larry Byars, and Ronald Nutt

PET Facility and Division of Nuclear Medicine, Department of Radiology, University of Pittsburgh, Pittsburgh, Pennsylvania; CTI PET Systems, Knoxville; and Byars Consulting, Oak Ridge, Tennessee




FIGURE 5. A 78-y-old man with squamous cell carcinoma of the lung. (A) Large isodense mass seen on CT appears on (B) PET scan as a hypermetabolic rim of increased FDG uptake, with necrotic center. (C) Fused image shows good alignment of 2 modalities. Lymph node in mediastinum (arrow) also demonstrated increased FDG uptake.




FIGURE 6. A 69-y-old man with diagnosed primary esophageal adenocarcinoma. (A) CT image. (B) PET image shows abnormal FDG uptake in the thorax. (C) Fused PET/CT image localizes uptake to specific lymph node (arrow).




FIGURE 7. A 38-y-old woman with history of unresectable pancreatic cancer. Laparotomy revealed presence of liver metastases. (A) CT image. (B) Difficulty of accurately localizing FDG uptake can be seen from PET image. (C) Fused image enabled uptake to be localized to pancreas and not to transverse colon as had originally been thought.

The combined PET/CT approach offers extensive possibilities for improving the diagnosis and staging of tumors, identification and localization of disseminated disease, improving radiotherapy treatment planning, and monitoring the effects of chemotherapy and radiation therapy.

Staging of Non-Small-Cell Lung Cancer with Integrated PET and CT

- 49 pats
- Extrathoracic metastases were confirmed histopathologically or by at least one other imaging method.
- PET/CT provided 24 items of additional information in 20/49 patients (41 %).

Table 1. Comparison of the Diagnostic Accuracy of Integrated PET-CT with CT Alone, PET Alone, and Visual Correlation of PET and CT Images.*

Variable	P Value
Tumor stage (n=40)	
PET-CT vs. CT alone	0.001† ✓
PET-CT vs. PET alone	<0.001† ✓
PET-CT vs. visual correlation of PET and CT	0.013† ✓
Node stage (n=37)	
PET-CT vs. CT alone	0.12 ✓
PET-CT vs. PET alone	0.013† ✓
PET-CT vs. visual correlation of PET and CT	0.021 ✓



FDG-PET/CT in re-staging of patients with lymphoma

Table 1. Region-based ($n=135$) sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of the different imaging modalities in lymphoma



Imaging modality	Sensitivity (%)	Specificity (%)	Positive predictive value (%)	Negative predictive value (%)	Accuracy (%)
CT	61	89	54	92	84
FDG-PET/CT	96	99	96	99	99

Table 2. Patient-based ($n=27$) sensitivity, specificity, positive predictive value, negative predictive value and accuracy of the different imaging modalities in lymphoma

Imaging modality	Sensitivity (%)	Specificity (%)	Positive predictive value (%)	Negative predictive value (%)	Accuracy (%)
CT	78	54	65	70	67
FDG-PET/CT	93	100	100	93	96



Scientific Publications



HardWare Fusion

Commercial scanners on the market in 2001!
Last stand alone PET on the market in 2006!

The Nobel Prize in Physiology or Medicine 2003



Paul C. Lauterbur
University of Illinois
Urbana, IL, USA
1929-2007




Sir Peter Mansfield
University of Nottingham, School of
Physics and Astronomy
Nottingham, United Kingdom
1919-2017

"for their discoveries concerning magnetic resonance imaging"


The Tracer is the Key

Gamma camera



Radio Pharmacon

- Bone
- Receptors
- Perfusion
- Ventilation
- Kidney function
- Blood cells
-



PET




Tracer

¹⁸F or ¹¹C or ¹⁵O


and

Active substance
(FDG or ACE or....)

- Metabolism
- Receptors
- Perfusion
- Amino acid
- Fatty acid
-




Warburg effect



Published by AAAS

M G Vander Heiden et al. Science 2009;324:1029-1033

Tumour Cell Biology



Concentration and Resolution



Modality	Conc at target		Resolution (mm)
PET	picomolar	(10^{-12})	3-6
SPECT	nanomolar	(10^{-9})	4-12
Gd MRI	milli-micromolar	(10^{-3-4})	< 0.5
CE CT	milli	(10^{-3})	< 0.5

PET or SPECT

- Function/molecular/metabolic imaging

CT

- Attenuation correction
- Structural/Morphological imaging

FDG Dosage



1 sugar lump = 3 000 000 μg

...or....

200 000 sugar grains

Approx 3 μg FDG per patient

...or....

1/5 sugar grain

FDG PET/CT Makes a Difference

VOLUME 26 NUMBER 13 MAY 1 2008


JOURNAL OF CLINICAL ONCOLOGY

ORIGINAL REPORT


Impact of Positron Emission Tomography/Computed Tomography and Positron Emission Tomography (PET) Alone on Expected Management of Patients With Cancer: Initial Results From the National Oncologic PET Registry

Bruce E. Hillner, Barry A. Siegel, Dawei Liu, Anthony F. Shields, Ilana F. Garcon, Lucy Hanna, Sharon Hartson Stone, and R. Edward Coleman

Based on 22 975 studies



Tracer targets



- PET radiotracers targeting tumors used for the **assessment of blood flow** (MBF; ^{15}O -water, ^{13}N -ammonia, ^{82}Rb , ^{11}C -acetate),
- **metabolism** (^{18}F -FDG, ^{11}C -glucose, ^{18}F -FTHA, ^{11}C -palmitate, ^{11}C -acetate, ^{18}F -FGln, and ^{11}C -acetoacetate),
- **key markers** (^{18}F -FAZA, ^{18}F -FLT, ^{18}F -FET, ^{18}F -FCh, and ^{11}C -choline).

Tracer Distribution



FDG

Metabolism



Acetat

Energy or membrane synthesis



FLT

Proliferation



NAF


Ostogenesis

Neuro Applications




UMEÅ UNIVERSITET

Biomarkers in Dementia




Tracer Distribution


Amyloid PET imaging



[18]F-flutemetamol amyloid PET in an MCI patient that later developed AD




[18]F-flutemetamol amyloid PET in a cognitively healthy elderly




TAU PET

Dopamine transporter imaging with [18F]FE-PE2I PET and [123I]FP-CIT SPECT—a clinical comparison

PE2I-PET



Fp-CIT-SPECT



Conclusion: DAT imaging with FE-PE2I PET yields excellent basic diagnostic differentiation in early-stage PS, at least as good as FP-CIT SPECT.

Lymphoma



UMEÅ UNIVERSITET

Change in Guidelines

VOLUME 32 · NUMBER 27 · SEPTEMBER 20 2014

JOURNAL OF CLINICAL ONCOLOGY

SPECIAL ARTICLE

Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification

Bruce D. Cheson, Richard I. Fisher, Sally F. Barrington, Franco Cavalli, Lawrence H. Schwartz, Emanuele Zucca, and T. Andrew Lister

Deauville Criteria 2014

Score	Definition	
1	No uptake	CMR
2	Uptake \leq mediastinum	
3	Uptake $>$ mediastinum but \leq liver	Prob CMR
4	Moderately increased uptake compared to the liver	
5	Markedly increased uptake compared to the liver and/or new lesions	
X	New areas of uptake unlikely to be related to lymphoma	

- A baseline PET/CT should always be performed prior to initiation of therapy.
- An interim-PET must be performed early on during induction chemotherapy.

FDG-PET/CT in B-cell Lymphoma and Hodgkins disease

- Initial staging → altered therapy occurs in about 9%
- response assessment → residual fibrotic masses vs viable tumor
- Post-treatment PET-neg → more favorable PFS outcomes; ($P < .001$)
- Interim PET neg → higher 2-year PFS ($P=0.0046$)
- Interim PET pos → change of treatment
- No bone marrow biopsy if clearly positive focal marrow uptake by PET-CT

Mb Hodgkin!



First two rounds of chemo




Complete metabolic
response after two rounds of
ABVD



3




2



1

In 17 of the 638 patients (2.5%), increased, symmetrical FDG uptake was found in the shoulder region that was not related to muscular structures on CT.



Short communication

Brown adipose tissue: a factor to consider in symmetrical tracer uptake in the neck and upper chest region


Thomas F. Hany¹, Esmail Gharehpapagh¹, Ehab M. Kamel¹, Alfred Buck¹, Jean Himms-Hagen², Gustav K. von Schulthess¹

¹ Department of Medical Radiology, Division of Nuclear Medicine, University Hospital Zurich, Rämistrasse 100, 8091 Zurich, Switzerland

² Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Canada



Eur J Nuc Med (2002) 29:1393–1398



Lung Cancer




UMEÅ UNIVERSITET

FDG-PET/CT in NSCLC


- 590 292 pat – 6118 with NSCLC
- Unsuspected distant metastases in 11-16.5% of patients
- Changes in stage in 27-62%
- Changes in medical management in 25-37%

Morgensztern et al 2008 J Thor Surg




Stage Migration in Lung Cancer

NSCLC




Patients at risk	0	6	12	18	24	30	36	42	48	54	60	66	72
PET scan Yes	491	444	364	305	247	172	114	77	53	32	15	4	
PET scan No	107	86	73	51	38	23	22	18	11	9	5	0	




Patients at risk	0	6	12	18	24	30	36	42	48	54	60	66	72
PET scan Yes	491	320	187	132	95	69	43	31	21	10	4	1	
PET scan No	107	81	27	15	10	4	3	3	2	1	0	0	

Vokes et al *Journal of Thoracic Oncology* 2018 Vol. 13 No. 8: 1183

limited-stage small cell lung cancer treated with chemoradiation.




Number at Risk	0	12	24	36	48	60	72
No PET	397	225	107	73	57	42	21
PET	397	280	164	121	94	55	34




Number at Risk	0	12	24	36	48	60	72
No PET	397	225	107	73	57	42	21
PET	397	280	164	121	94	55	34

Extensive stage small cell lung cancer treated with chemoradiation.



Number at Risk	0	12	24	36	48	60	72
No PET	5,347	837	149	77	55	39	29
PET	793	232	63	30	18	9	4





Number at Risk	0	12	24	36	48	60	72
No PET	5,347	837	149	77	55	39	29
PET	793	232	63	30	18	9	4

Test Performance of Positron Emission Tomography and Computed Tomography for Mediastinal Staging in Patients with Non-Small-Cell Lung Cancer


A Meta-Analysis

- 39 studies - 1959 patients – unknown number of lymph nodes




	Sens (%)	Spec (%)
CT	61	79
PET normal sized nodes	82	93
PET enlarged nodes	100	78

Lung Cancer x 2




Lung Cancer x 2



Lung Cancer x 2






RT
Survival time 1y



Surgery
Cured – so far 4y

Distant Metastases in Lung Cancer

- FDG PET/CT to rule out metastatic disease in Stage I, II and IIIA Disease, as well as IIIB (T1-2, N3 and T3-4, N2) and IV (M1b)



MacMahon et al
Radiology 2017;
284:228–243

Guidelines for Management of Incidental Pulmonary Nodules Detected on CT Images: From the Fleischner Society 2017¹



Radiology

Fleischner Society 2017 Guidelines for Management of Incidentally Detected Pulmonary Nodules in Adults

A: Solid Nodules*

Nodule Type	Size			Comments
	<6 mm (<100 mm ³)	6–8 mm (100–250 mm ³)	>8 mm (>250 mm ³)	
Single				
Low risk [†]	No routine follow-up	CT at 6–12 months, then consider CT at 18–24 months	Consider CT at 3 months, PET/CT, or tissue sampling	Nodules <6 mm do not require routine follow-up in low-risk patients (recommendation 1A).
High risk [†]	Optional CT at 12 months	CT at 6–12 months, then CT at 18–24 months	Consider CT at 3 months, PET/CT, or tissue sampling	Certain patients at high risk with suspicious nodule morphology, upper lobe location, or both may warrant 12-month follow-up (recommendation 1A).

Small Lung nodules




Prostate Cancer




UMEÅ UNIVERSITET




PROGRESSION OF PCA






^{68}Ga - & ^{177}Lu -labelled PSMA targeting agents




PSMA PET/MR: Uptake PZ left



DWI




Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer—Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis




Prostate cancer with PSMA PET CT

Baseline




FU@2.5

y



3. Finding?

Metastasis





ColoRectal Cancer




UMEÅ UNIVERSITET

Coloncancer - Uppföljning




Vänstersidig hemicolektomi för en avancerad tumör med överväxt på laterala bukväggen för 1 år sedan. PAD visade tveksam radikalitet - Dukes C. Adjuvant cyt. CT-kontroll visar 2,5 cm stor tumör ventralt till vänster i bukväggen. I övrigt ingen metastasering.


Metastast - Recidiv



Metastas - Recidiv



Metastas - Recidiv



FDG PET/MR in Rectal Cancer





Fig. 3 Focally increased metabolic activity in the right liver lobe without corresponding morphological changes in the second FDG-PET/CT imaging after neoadjuvant treatment. **a** FDG-PET; **b** FDG-PET/CT; **c** CT






Fig. 5 A PET/MR image of the same patient as that in Fig. 3. **a** Transaxial T2 weighted sequence perpendicular to the tumour; **b** FDG-PET/MR image with a T2 weighted MR sequence; **c** Transaxial diffusion-weighted sequence ($b = 800 \text{ s/mm}^2$) **d** Static 3D MAC PET image

Rectal cancer: a methodological approach to matching PET/MRI to histopathology



- Both histopathology and MRI (surgical specimen)
- Only in MRI (surgical specimen)
- Only in histopathology








What about the size?




UMEÅ UNIVERSITET

Very Small Tumours



Education and Training?


Would you like to receive education and attend seminars about CT (computed tomography)?



Do you agree that in order to be prepared for the employment and future practice of imaging it's important to have some knowledge of radiology as well as NM techniques?



If no, would you support a joint training program if nuclear medicine physicians did so too?



FDA-Approved PET Radiopharmaceuticals 2023

^{11}C choline

^{64}Cu dotatate (Detectnet™)

^{18}F florbetaben
(Neuraceq™)

^{18}F florbetapir (Amyvid™)

^{18}F flortaucipir (Tauvid™)

^{18}F fluciclovine (Axumin™)

Fluorine-18 fludeoxyglucose
(FDG)

^{18}F fluorodopa

^{18}F fluoroestradiol
(Cerianna™)

^{18}F flutemetamol
(Vizamyl™)

^{18}F piflufolastat
(PYLARIFY®)

^{18}F sodium fluoride

^{68}Ga DOTATATE (Netspot™)



^{68}Ga DOTATOC

^{68}Ga gozetotide (Illuccix®,
Locametz®)


^{13}N ammonia


^{82}Rb chloride (Cardiogen-
82®)

2023 PET/CT and PET/MRI clinical studies




Hallmarks of Cancer






How to use Hybrid Imaging




Lambin et al EJC 2012

- Use information from both PET and CT/MR!
- Structure the report
 1. PET-pathology with corresponding CT/MR-findings
 2. CT/MR-pathology without PET pathology
 3. Summary of the disease



PET/CT
PET/MR

Wishes for the Future!



Clever use of AI!
ONE specialist-education in Imaging!
Less complicated translation in tracer
development!
Micro-dosing equipments for PET-tracer – more
lika a "coffe mchine"!

NUKLEARMEDICINSKT VÅRMÖTE 2023

31 MAJ - 2 JUNI



Collaborators at:

- Umeå university,
- Umeå university hospital
- Umeå center for functional Brain imaging
- Grant givers
- ESR
- ESHI
- Others